英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
floscio查看　floscio　在百度字典中的解释百度英翻中〔查看〕
floscio查看　floscio　在Google字典中的解释Google英翻中〔查看〕
floscio查看　floscio　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Gilead Sciences
    Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
  • Gilead U. S. Investment to Create $43 Billion in Value to U. S. Economy
    Gilead to invest $32 billion in U S manufacturing and R D through 2030 and create more than 3,000 direct and indirect jobs by 2028 Foster City, Calif , May 7, 2025 – Gilead Sciences is committed to advancing world-class science and driving innovation — with the United States at the heart of our operations Today, our U S R D and
  • Gilead Sciences: Company
    Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
  • Medicines - Gilead Sciences
    Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology inflammation
  • Virology, Inflammation, Oncology Pipeline | Gilead
    Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, inflammation Learn about our pipeline
  • First Clinical Data for Gilead’s Investigational Once-Yearly . . .
    Gilead researchers have developed 12 HIV medications, including the first single-tablet regimen to treat HIV, the first antiretroviral for pre-exposure prophylaxis (PrEP) to help reduce new HIV infections, and the first long-acting injectable HIV treatment medication administered twice-yearly
  • Gilead Sciences, Inc. - Investor Relations
    At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in
  • Gilead Sciences: Career Opportunities
    Explore career opportunities and jobs at Gilead Sciences, a biopharma company with an inclusive culture where all employees can help build a healthier world
  • Gilead Sciences Announces 2. 6 Percent Increase in First Quarter 2025 . . .
    FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2 6% in the company’s quarterly cash dividend, beginning in the first quarter of 2025 The increase will result in a quarterly dividend of $0 79 per share of common stock
  • Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV . . .
    FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing





中文字典-英文字典  2005-2009